Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,866.03 3.72 0.20%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,417.53 -0.15 -0.00%
TOPIX 1,166.59 0.04 0.00%
HANG SENG 22,760.24 64.23 0.28%

Celgene Corporation to Webcast at Two Upcoming Investor Conferences and the American College of Rheumatology



  Celgene Corporation to Webcast at Two Upcoming Investor Conferences and the
  American College of Rheumatology

Credit Suisse Healthcare Conference Piper Jaffray Healthcare Conference 2012

Business Wire

SUMMIT, N.J. -- November 07, 2012

Celgene Corporation (NASDAQ: CELG) today announced its presentations at two
upcoming investor conferences will be webcast live and will be available in
the investor relations section of the company’s web site at www.celgene.com.
Celgene management will provide an overview of the company.

  * On Wednesday, November 14, 2012, Celgene will present at the Credit Suisse
    Healthcare Conference at 5:30 p.m. ET.
  * On Tuesday, November 27, 2012, Celgene will present at the Piper Jaffray
    24^th Annual Healthcare Conference at 9:00 a.m. ET.

Celgene will also  host a webcast of an investor event at the American College
of Rheumatology (ACR) meeting on Tuesday, November 13 at 6:00 p.m. ET. Members
of Celgene’s management team and clinical investigators will discuss the
PALACE-1 results in psoriatic arthritis. The meeting will be webcast live and
will be available in the investor relations section of the Company’s web site
at www.celgene.com.

About Celgene

Celgene Corporation, headquartered in Summit, New Jersey, is an integrated
global biopharmaceutical company engaged primarily in the discovery,
development and commercialization of novel therapies for the treatment of
cancer and inflammatory diseases through gene and protein regulation. For more
information, please visit the company’s Web site at www.celgene.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are generally
statements that are not historical facts. Forward-looking statements can be
identified by the words "expects," "anticipates," "believes," "intends,"
"estimates," "plans," "will," “outlook” and similar expressions.
Forward-looking statements are based on management’s current plans, estimates,
assumptions and projections, and speak only as of the date they are made. We
undertake no obligation to update any forward-looking statement in light of
new information or future events, except as otherwise required by law.
Forward-looking statements involve inherent risks and uncertainties, most of
which are difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of factors,
many of which are discussed in more detail in our Annual Report on Form 10-K
and our other reports filed with the Securities and Exchange Commission.

In addition to financial information prepared in accordance with U.S. GAAP,
this press release also contains adjusted financial measures that we believe
provide investors and management with supplemental information relating to
operating performance and trends that facilitate comparisons between periods
and with respect to projected information. These adjusted measures are
non-GAAP and should be considered in addition to, but not as a substitute for,
the information prepared in accordance with U.S. GAAP. We typically exclude
certain GAAP items that management does not believe affect our basic
operations and that do not meet the GAAP definition of unusual or
non-recurring items.  Other companies may define these measures in different
ways. See the attached Reconciliations of GAAP to adjusted Net Income for
explanations of the amounts excluded and included to arrive at adjusted net
income and adjusted earnings per share amounts for the three- and nine-month
periods ended September 30, 2012 and 2011, and for the projected amounts for
the year ending December 31, 2012.

Contact:

Celgene Corporation
Jacqualyn A. Fouse, Ph.D, 908-673-9956
EVP, Chief Financial Officer
or
Patrick E. Flanigan III, 908-673-9969
VP, Investor Relations
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement